CBIO · Crescent Biopharma, Inc.
$16.23
-1.09 (-6.29%)
At close · Aug 20
Market Cap
$602.85M
Shares
37.14M
Named-executive compensation from the company's DEF 14A proxy statements — salary, bonus, stock and option awards, non-equity incentive, and the company-reported total per executive per fiscal year, exactly as disclosed in the Summary Compensation Table.
No Compensation Data
No Summary Compensation Table has been imported from this company's proxy statements yet.
Executive changes
| Person | Role | Change | Filed |
|---|---|---|---|
| Brian Hahn | Chief Financial Officer | Resigned | 2025-02-25 |
| Harout Semerjian | Board of Directors | Resigned | 2025-02-25 |
| Harout Semerjian | Chief Executive Officer | Resigned | 2025-02-25 |
| Rachel King | Board of Directors | Resigned | 2025-02-25 |
| Scott Koenig, M.D., Ph.D. | Board of Directors | Resigned | 2025-02-25 |
| Scott Jackson | Board of Directors | Resigned | 2025-02-25 |
| Mark Goldberg, M.D. | Board of Directors | Resigned | 2025-02-25 |
| Dr. Edwin Rock | Chief Medical Officer | Terminated | 2024-07-30 |
| Harout Semerjian | director | Appointed | 2022-05-20 |
| Scott Koenig | director | Appointed | 2022-05-20 |
| Scott Jackson | director | Appointed | 2022-05-20 |
| Harout Semerjian | director | Appointed | 2021-08-05 |
| Harout Semerjian | President and Chief Executive Officer | Appointed | 2021-08-05 |
| Rachel K. King | President and Chief Executive Officer | Retired | 2021-08-05 |
| Helen Thackray, M.D., FAAP | Senior Vice President and Chief Medical Officer | Resigned | 2021-02-23 |
Key facts
CIK
1253689
CUSIP
G2545C104
13F (30d)
77 filings
77 filers
Visit website
Investor relations